Lexaria Bioscience (LEXX) Total Debt (2011 - 2022)
Lexaria Bioscience (LEXX) posted Total Debt of $7906.0 for Q2 2022, little changed sequentially from $7926.0 in Q3 2021, and up 5.32% YoY from $7507.0 in Q2 2021.
Lexaria Bioscience (LEXX) Total Debt (2011 - 2022) Analysis & Trends
Lexaria Bioscience has reported Total Debt for 12 years, with the latest figure at $7906.0 in Q2 2022.
- Quarterly Total Debt rose 5.32% year-over-year to $7906.0 in Q2 2022, while the trailing twelve-month figure through May 2022 was $7906.0 (up 5.32% YoY) and the FY2021 annual result came in at $7926.0, down 91.13% from the prior year.
- Total Debt was little changed at $7906.0 in Q2 2022 per LEXX's latest filing, from $7926.0 in the prior quarter.
- Over five years, Total Debt peaked at $118037.0 in Q4 2020 and troughed at $1600.0 in Q1 2020.
- A 5-year average of $28395.8 and a median of $8518.0 in 2018 frame the typical range for Total Debt.
- The sharpest annual moves came in 2018 and 2019: Total Debt slumped 98.02% in 2018, then jumped 512.3% in 2019.
- Over 5 years, Total Debt stood at $21654.0 in 2018, then soared by 71.79% to $37200.0 in 2019, then surged by 217.3% to $118037.0 in 2020, then tumbled by 93.29% to $7926.0 in 2021, then retreated by 0.25% to $7906.0 in 2022.
- According to Business Quant data, Total Debt over the past three periods registered $7906.0, $7926.0, and $7507.0 for Q2 2022, Q3 2021, and Q2 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 9.34 Bn |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2022 | 7,906.00 |
| Aug 31, 2021 | 7,926.00 |
| May 31, 2021 | 7,507.00 |
| Feb 28, 2021 | 7,507.00 |
| Nov 30, 2020 | 118,037.00 |
| Aug 31, 2020 | 89,374.00 |
| May 31, 2020 | 58,351.00 |
| Feb 29, 2020 | 1,600.00 |
| Nov 30, 2019 | 37,200.00 |
| Aug 31, 2019 | 48,096.00 |
| May 31, 2019 | 20,995.00 |
| Feb 28, 2019 | 5,621.00 |
| Nov 30, 2018 | 21,654.00 |
| Aug 31, 2018 | 7,855.00 |
| May 31, 2018 | 9,110.00 |
| Feb 28, 2018 | 5,594.00 |
| Nov 30, 2017 | 25,018.00 |
| Aug 31, 2017 | 42,690.00 |
| May 31, 2017 | 7,446.00 |
| Feb 28, 2017 | 282,615.00 |